Michael Jain

50PUBLICATIONS
297CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)AutoimmunityCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Jul 08, 2026
Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.

|Jun 20, 2026
Expanded antigen-specific donor regulatory T cells for GVHD prevention.

|Apr 15, 2026
Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders.

|Feb 11, 2026
Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.

Rawan G Faramand, Zhuoer Xie, Michael D Jain

|Sep 11, 2025
Immune dysfunction after cancer remission: scar or disease?

Michael D Jain, Jonathan Cools-Lartigue

|Aug 26, 2025
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma.

Michael Winkelmann, Sandeep S Raj, Michael D Jain

Pageof 9

Frequent Collaborators

15 joint publications

Marco L Davila

15 joint publications

Frederick Locke

11 joint publications

Marion Subklewe

10 joint publications

Taiga Nishihori